Trade Palisade Bio, Inc. - PALI CFD

Trading Conditions

• Spread: 0.11
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 6.11
• Open: 6.05
• 1-Year Change: 300.66%
• Day's Range: 5.81 - 6.32

Palisade Bio, Inc. Company profile

About Palisade Bio Inc

Palisade Bio, Inc, formerly Seneca Biopharma, Inc., is a biopharmaceutical company. The Company is focused on developing therapies that helps patients with acute and chronic gastrointestinal problems from post-operative digestive enzyme damage. Its product candidate, LB1148, is a Phase III-ready protease inhibitor which is developed to reduce abdominal adhesions and help restore bowel function following surgery. It is engaged in developing oral product candidates to treat conditions driven by protease (intestinal digestive enzymes) escaping the intestines, including surgical problems and inflammatory conditions. Its LB1148 is an oral formulation of a serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Palisade Bio Inc revenues decreased from $11K to $0K. Net loss increased from $11.8M to $27.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest expense increase from $14K to $2.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$7.31 to -$3.41.

Equity composition

Common Stock $.01 Par, 03/11, 150M auth., 48,366,304 shares issd. Insiders & Strategic holders own 13.61%. IPO:1/07, 16.3M shares @ $1 per Share.